看起來你不是TradeKey.com的會員。 立即註冊,與全球超過7百萬的進口商和出口商建立聯繫。 点击注册--免费! |
BOOK A CALL
Book Call On Your Favorite Time

By Signing Up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services

Contact Us
product
Prev
Hyaluronic acid (HA)Successful Discussion on Clinical Trial Protocol
Next

Hyaluronic acid (HA)Successful Discussion on Clinical Trial Protocol

离岸价格

获取最新报价

( Negotiable )

|

- Minimum Order

国家:

China

型号:

-

离岸价格:

( Negotiable ) 获取最新报价

位置:

-

最小订单价格:

-

最小订单:

-

包装细节:

-

交货时间:

-

供应能力:

-

付款方式:

T/T

產品組 :

-

现在联系
1st 年

联系人 Ms. Angela Yan

Guoxiang Street, Wuzhong District, Suzhou City

现在联系

产品规格

  • Properties: Injection & Puncture Instrument

详情

Successful Discussion on Clinical Trial Protocol for PEG Embolic Microspheres in Uterine Fibroids Held in Suzhou
On August *7, ***4, a successful meeting was held at Suzhou Baodaiqiao International Hotel to discuss the clinical trial protocol for the treatment of symptomatic uterine fibroids using PEG (polyethylene glycol) embolization microspheres. The discussion, which was highly productive, focused on evaluating the efficacy and safety of PEG embolization microspheres in addressing this condition.
The PEG embolic microspheres from Suzhou Haowei offer a range of benefits that make them an ideal choice for the treatment of uterine fibroids. With a comprehensive range of specifications, the microspheres are available in sizes ranging in different sizes, ensuring uniform particle sizefor precise embolization. This precision helps to shorten surgery time, providing a significant advantage in clinical settings. The property of biodegradability ensures safety and effectiveness of the operation. Whats more, the embolic microspheres could loading a series of drug to enhance the operational effect in a comparatively short loading time.
Participants expressed confidence in the promising potential of this treatment, with the protocol receiving positive feedback from all involved. The clinical trial will involve multiple institutions across China, each playing a vital role in the research: Here are the lists:

Site Code Clinical Trial Site Department Investigator
*1 Beijing Obstetrics and Gynecology Hospital, Capital Medical University Department of Gynecologic Oncology Prof. Wang Jiandong
*2 The First Affiliated Hospital of Guangxi Medical University Department of Gynecology Dr. Fan Jiangtao
*3 Guangzhou Women and Children's Medical Center Department of Gynecology Dr. Huang Shenjiao
*4 Hangzhou First People's Hospital Department of Gynecology Dr. Tong Jinyi
*5 West China Second University Hospital, Sichuan University Department of Radiology Dr. Ning Gang
*6 The Second Affiliated Hospital of Soochow University Department of Interventional Radiology Dr. Jin Yong
*7 Suzhou Municipal Hospital Department of Vascular Surgery Dr. Zhou Dayong
*8 The Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University Department of Interventional Diagnosis and Treatment Dr. Si Guangyan
*9 Yantai Yuhuangding Hospital Department of Gynecology Dr. Wang Shaoguang
The study is sponsored by Suzhou Haowei Medical Technology Co., Ltd., and will be led by Professor Wang Jiandong as the principal investigator at the primary site.

国家: China
型号: -
离岸价格: ( Negotiable ) 获取最新报价
位置: -
最小订单价格: -
最小订单: -
包装细节: -
交货时间: -
供应能力: -
付款方式: T/T
產品組 : -
Hyaluronic acid (HA)Successful Discussion on Clinical Trial Protocol

Send a direct inquiry to this supplier

至:

Ms. Angela Yan < Suzhou Haowei Medical Technology Co., Ltd >

我想知道: